Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Avelas Biosciences to Present at Piper Jaffray Healthcare Conference | ||
| By: PR Newswire Association LLC. - 21 Nov 2017 | Back to overview list |
|
SAN DIEGO, Nov. 21, 2017 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced that Carmine N. Stengone, president and chief executive officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 4:50 p.m. EST (1:50 p.m. PST) in New York City. About Avelas Biosciences Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. A Phase 2 clinical trial for AVB-620 in breast cancer is ongoing. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded by Avalon Ventures on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.
View original content:http://www.prnewswire.com/news-releases/avelas-biosciences-to-present-at-piper-jaffray-healthcare-conference-300559748.html SOURCE Avelas Biosciences, Inc. 
|
||
|
||
 | Back to overview list | |